Deferoxamine Mesylate in patients with intracerebral haemorrhage: a Multi-Center, Randomised, Double-Blind, Placebo-Controlled, Phase II Trial

BACKGROUND: Iron, from hemolyzed blood, is implicated in secondary injury after intracerebral haemorrhage (ICH). We aimed to evaluate the safety of the iron chelator, Deferoxamine Mesylate (DFO), and whether it merits investigation in a Phase-III study to definitively assess its effectiveness in imp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Neurol
Autori principali: Selim, Magdy, Foster, Lydia D, Moy, Claudia S, Xi, Guohua, Hill, Michael D, Morgenstern, Lewis B, Greenberg, Steven M, James, Michael L, Singh, Vineeta, Clark, Wayne M, Norton, Casey, Palesch, Yuko Y, Yeatts, Sharon D
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494117/
https://ncbi.nlm.nih.gov/pubmed/30898550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(19)30069-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi